NCT Number: NCT04399954
For 28 days, 30 participants aged 3 to 18 years of age (inclusive) with a condition requiring a ketogenic diet will incorporate Ketoflo into their usual dietary regime. Ketoflo is a nutritionally complete Food For Special Medical Purposes and is suitable for administration by both tube feeding and use as a sip feed. Data on gastrointestinal tolerance, participants adherence to recommended intakes and their thoughts on the product's palatability will be self-reported in Daily Study Diaries.
Looking for future studies?
Notify Me3 year–18 year
All sexes
Interventional
Not applicable
Royal Aberdeen Children's Hospital, Aberdeen, United Kingdom
This is a 28-day prospective study to evaluate the acceptability of Ketoflo, in terms of GI tolerance, adherence to recommended intakes and palatability. The product's nutritional suitability for use in a ketogenic diet will also be evaluated by recording ketone levels and seizure frequency measured as part of usual clinical care.
Ketoflo is nutritionally complete liquid feed for use in the dietary management of epilepsy or other neurometabolic conditions requiring a ketogenic diet. It is designed to be nutritionally complete from 3-18 years and can be used as a supplementary feed thereafter.
Ketoflo has been designed in liaison with Key Opinion Leaders and will offer an additional choice of prescribe-able feeds for use in the ketogenic diet.
The study will involve 30 participants, aged between three and eighteen years of age (inclusive), who are already established on a ketogenic diet for at least three months before the study begins.
Participants will self-report data in Daily Study Diaries over the course of the study. Data will also be collected by the Investigators in Baseline CRFs and End of Study CRFs for all participants. Any data collected for the study will be anonymised before being relayed to the sponsor.
The data generated by the trial will be used to support a submission by Vitaflo (International) Ltd. to the Advisory Committee on Borderline Substances (ACBS) for Ketoflo to become reimbursable on prescription in the UK. The data will also be used in a submission to the General Medical Services in the Republic of Ireland.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
i) Diagnosis of a condition requiring a ketogenic diet (KD) e.g. intractable epilepsy, Glut-1 deficiency syndrome (Glut-1 DS) etc.
ii) Aged 3 - 18 years of age (inclusive).
iii) Established on a ketogenic diet for at least 3 months under the supervision of a clinician and/or dietitian trained in the use of the KD.
iv) Requirement for a liquid ketogenic feed.
v) In the opinion of the investigator, the participant (and parent/guardian, if relevant) is/are able to comply with the study protocol requirements and complete the diary and questionnaire.
vi) Willingly given, written, informed consent from participant (or parent/guardian, if relevant)
vii) Willingly given, written assent (if appropriate).
Exclusion criteria
i) Inability to comply with the study protocol, in the opinion of the investigator.
ii) Under 3 years of age or over 18 years of age.
iii) Medical conditions in which the KD is contraindicated.
iv) Previous clinical evaluation indicating unsuitability for the KD.
Ketoflo is a ready to use liquid feed for the dietary management of epilepsy and other conditions that may require a ketogenic diet. It has a 4:1 ratio of fat to carbohydrate and protein and can be administered enterally via a tube feeding or oral consumption.
Time frame: Days 1 - 7 and days 21 - 28.
Participants will self-report any gastrointestinal symptoms experienced over the course of the study in Daily Study Diaries.
Time frame: Days 1 - 28.
Participants will record the amount of Ketoflo taken each day compared to the amount recommended by their dietitian.
Time frame: Day 28.
Participants will answer questions relating to Ketoflo's palatability and ease of use following the end of the study.
Time frame: Days 1 - 28
Ketoflo's nutritional suitability will be assessed by evaluating ketone levels (mmol/l) recorded by participants as part of routine care. These data will be recorded in the Daily Study Diaries.
Time frame: Days 1 - 28
Ketoflo's nutritional suitability will be assessed by evaluating seizure frequency (number per day) recorded by participants as part of routine care. These data will be recorded in the Daily Study Diaries.
Vitaflo International, Ltd
Industry
A Study to Evaluate the Acceptability of Ketoflo, a Food for Special Medical Purposes (FSMP) for Use in the Dietary Management of Epilepsy or Neurometabolic Conditions Requiring a Ketogenic Diet (KD)
Acronym: Ketoflo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07222878
Alzheimer Disease, Brain Diseases
Lincoln, Nebraska, United States
View Trial DetailsNCT03278210
Brain Diseases, Central Nervous System Diseases
Lille, France
View Trial DetailsNCT05015868
Brain Diseases, Central Nervous System Diseases
Bosisio Parini, lecco, Italy
View Trial DetailsNCT03646240
Brain Diseases, Central Nervous System Diseases
Seattle, Washington, United States
View Trial Details